Be the first person to write a business review for Onyx Pharmaceuticals, Inc.

Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas. Opexa Therapeutics, Inc. operates as a biopharmaceutical company, developing autologous cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS) and diabetes. These therapies are based on Opexa's proprietary T-cell and adult stem cell technologies. The company's products include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS. The adult stem cell technology is in the preclinical development stage. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006.

Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

Oragenics, Inc. company was founded in 1996 and is based in Alachua, Florida. Oragenics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of products and technologies associated with oral health, antibiotics, and other general health benefits. The company develops Probiora3, an oral probiotics technology that employs three natural strains of beneficial bacteria, which promote oral health; LPT3-04 for weight loss; and DPOLT or differentially protected orthogonal lantionine technology, which is a solid or liquid phase peptide synthesis platform technology that has various applications for the manufacture of commercially important bioactive peptides. It is also developing Mutacin 1140, an antibiotic with antimicrobial activity against gram-positive bacteria, including methicillin-resistant and vancomycin-resistant Staphylococcus aureus; Proteomic-based In-Vivo Induced Antigen Technology (PIVIAT) and Proteomic-based Change Mediated Antigen Technology (PCMAT) diagnostic platforms that enable the identification of novel and potentially important gene targets associated with the natural onset and progression of infections, cancers, and other diseases in humans and other living organisms, including plants; and SMaRT Replacement Therapy, which is a painless topical treatment for protection against tooth decay. The company primarily operates in the United States and Mexico. It was formerly known as Oragen, Inc.

OrthoLogic Corp., doing business as Capstone Therapeutics, focuses on the development and commercialization of therapeutic peptides and other molecules for patients with under-served conditions. The company's product includes Chrysalin, or TP508, a 23-amino acid synthetic peptide, which is under pre-clinical testing for vascular applications, such as acute myocardial infarction and chronic myocardial ischemia. It also offers AZX100, a synthetic 24-amino acid peptide to relax smooth muscle, which modulates blood pressure and the function of blood vessels, airways, sphincters, the gastrointestinal tract, and the genitourinary tract. AZX100 is also evaluated for medical and commercial applications, such as treatment of pulmonary disease, prevention of hypertrophic and keloid scarring, and intimal hyperplasia. The company was formerly known as IatroMed, Inc. and changed its name to OrthoLogic Corp. in July 1991. OrthoLogic Corp. was founded in 1987 and is based in Tempe, Arizona.

OSI Pharmaceuticals, Inc. company was founded in 1983 and is based in Melville, New York. OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of molecular targeted therapies for the treatment of unmet medical needs in oncology, diabetes, and obesity. Its flagship product, Tarceva is a small molecule therapeutic designed to inhibit the receptor tyrosine kinase activity of the protein product of the HER1/EGFR gene. The company also offers Novantrone, a mitoxantrone for injection concentrate. OSI Pharmaceuticals products in Phase I clinical trials include OSI-906, an oral small molecule IGF-1R inhibitor for various cancers, including NSCLC, breast, pancreatic, prostate, colorectal, adrenocortical, and ovarian; PSN821, an oral small molecule drug with anti-diabetic and appetite suppressing effects developed for the treatment of type 2 diabetes; PSN602, a novel dual serotonin and noradrenaline reuptake inhibitor for the long-term treatment of obesity; and OSI-027, a small molecule TORC1/TORC2 inhibitor to supersede first generation mTOR inhibitors. The companys other development programs include OSI-296, a novel potent TKI developed to block compensatory signaling in epithelial tumor cells; OSI-930, a multi-targeted tyrosine kinase inhibitor that acts as a potent co-inhibitor of the receptor tyrosine kinases c-kit and the vascular endothelial growth factor receptor-2; OSI-632, an anti-angiogenesis agent; and CP-868,596, a PDGFR inhibitor. OSI Pharmaceuticals has collaboration agreements with Genentech, Inc.; Roche; and AVEO Pharmaceuticals, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.